![](/img/cover-not-exists.png)
839TiPA phase II clinical trial of radium-223 activity in patients (pts) with metastatic castration-resistant prostate cancer (mcrpc) with asymptomatic progression while on abiraterone acetate or enzalutamide besides AR-V7 mutational status (EXCAAPE)
Carles Galceran, J., Bonfill Abella, T., Borrega, P., Collado, R., Garde, J., Gonzalez del Alba Baamonde, M.A., Grande Pulido, E., Mellado, B., Mendez Vidal, M.J., Piulats Rodriguez, J.M., Morales BarVolume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx370.056
Date:
September, 2017
File:
PDF, 48 KB
english, 2017